CRVO

CervoMed is a pre-revenue, clinical-stage biotech whose entire value rests on one asset, neflamapimod, for dementia with Lewy bodies (DLB). The MD&A is unambiguous: 'we have not generated any revenue from product sales,' 'we have never been profitable,' and — the decisive line — management states existing cash, equivalents and marketable securities ($20.9M per the filing) will NOT fund operations for 'at least twelve months from issuance,' with the financials prepared on a going-concern basis. That is an explicit solvency warning, not boilerplate. The XBRL cash figure of $8.24M against a $23.4M annual operating cash burn implies the company must raise capital, and with only 9.26M shares and a $33M market cap, any raise is likely to be sharply dilutive at a depressed $3.55 price.

The numbers reinforce the qualitative picture rather than offset it. FY2025 net loss widened to -$27.0M from -$16.3M, operating cash flow was -$23.4M, and the accumulated deficit reached -$97.7M. The small 'revenue' line ($4.01M, down 58.9%) is not product sales — it is non-recurring grant/collaboration income, so headline P/S (8.2x) and the garbled P/E/EPS fields are meaningless for a company with no commercial product. Stockholders' equity fell 53.5% to $18.2M as the deficit compounds. The one bright spot — low leverage (liabilities/equity 0.26x) — is cold comfort when the equity itself is being consumed by cash burn.